PulseAugur
实时 12:09:06
中文(ZH) 中信建投:2026医保目录调整引入预申报机制,进一步加快创新药准入

China to speed up innovative drug access with new medical insurance catalog rules

CITIC Securities research indicates that the 2026 medical insurance catalog adjustment will introduce a pre-declaration mechanism to expedite the inclusion of innovative drugs. This adjustment includes expanding the scope of eligible drugs, extending the application window for conditionally approved drugs, and establishing a coordinated pricing mechanism for competitive drugs. The policy aims to support genuine and differentiated innovation while maintaining the basic function of medical insurance. AI

影响 Policy changes in China's medical insurance catalog could accelerate the adoption of innovative drugs, potentially impacting AI-driven drug discovery and development.

排序理由 The cluster discusses significant policy changes in China's medical insurance system that impact the pharmaceutical industry. [lever_c_demoted from significant: ic=1 ai=0.4]

在 36氪 (36Kr) 阅读 →

AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →

报道来源 [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    CITIC Securities: 2026 Medical Insurance Catalog Adjustment Introduces Pre-declaration Mechanism, Further Accelerating Innovative Drug Access

    36氪获悉,中信建投研报称,2026年医保目录调整工作方案在延续常态化调整机制的基础上,主要在以下几方面实现突破:一是首次引入"预申报"机制,二是目录外药品申报条件新增3条,将商保创新药目录内药品、附条件批准转常规批准的药品、以及此前因未能成功续约被调出目录品种的同通用名药品纳入申报范围,三是明确附条件批准上市的药品最多可享受"5年+3年"的申报窗口期,四是续约规则进一步完善,五是竞价药品医保支付标准与挂网价协同机制建立。在保持基本医保"保基本"定位的同时,充分体现了"真支持创新、支持真创新、支持差异化创新"的政策导向,看好相关创新药及制药企业。